Shelly Engfer-Triebenbach was diagnosed with stage 4, nsclc in 2013. The ALK mutation was not discovered until four months after diagnosis. Her treatment thus far has been: 12 rounds of two different chemotherapies, 9 months on Crizotinib, 28 months on the Brigatinib (Alunbrig) trial, currently on month 20 of the Lorlatinib trial. She has also had one SRS treatment in 2018.
As a patient activist, Shelly mentors the newly diagnosed and feels empowered raising her voice on Capital Hill. She also enjoys working with pharmaceutical companies, serving on their patient advisory panels and speaking to their sales representatives. Shelly also partners with many lung advocacy groups including: A Breath of Hope, GO2 Foundation, IASLC, LCFA and Lungevity. She is excited to be a founding member of the patient group ALKFusion: “Patient centric research with a focus on collaboration and disease management.”
Most recently, Shelly was named a patient ambassador with the GO2 foundation, and a patient participant in the new STARS program with IASLC. She lives in rural Minnesota with her husband and two children.
Twitter: @shelly_et http://twitter.com/shelly_et